Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
SSY Group ( (HK:2005) ) has issued an announcement.
SSY Group Limited has announced that its drug Azilsartan has received approval from the National Medical Products Administration of China for registration as a bulk drug. This development marks a significant step in the company’s product offerings, potentially enhancing its market position in the hypertension treatment sector.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group Limited operates in the pharmaceutical industry, focusing on the development and production of medical products. The company’s primary products include bulk drugs and pharmaceutical preparations, with a market focus on China.
Average Trading Volume: 14,474,648
Technical Sentiment Signal: Sell
Current Market Cap: HK$8.91B
Learn more about 2005 stock on TipRanks’ Stock Analysis page.